Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

yiling pharmaceutical, inc. - levocetirizine dihydrochloride (unii: sod6a38aga) (levocetirizine - unii:6u5ea9rt2o) - levocetirizine dihydrochloride 5 mg - 1.2 chronic idiopathic urticaria levocetirizine dihydrochloride is indicated for the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 months of age and older. the use of levocetirizine dihydrochloride tablet is contraindicated in: 4.1 patients with known hypersensitivity patients with known hypersensitivity to levocetirizine or any of the ingredients of levocetirizine dihydrochloride tablets, or to cetirizine. observed reactions range from urticaria to anaphylaxis [see adverse reactions (6.2)]. 4.2 patients with end-stage renal disease patients with end-stage renal disease (clcr < 10 ml/min) and patients undergoing hemodialysis 4.3 pediatric patients with impaired renal function children 6 months to 11 years of age with impaired renal function 8.1 pregnancy risk summary available data from published literature and postmarketing experience with levocetirizine use in pregnant women are insufficient to identify any drug-ass

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

avkare, inc. - levocetirizine dihydrochloride (unii: sod6a38aga) (levocetirizine - unii:6u5ea9rt2o) - levocetirizine dihydrochloride 5 mg - 1.2 perennial allergic rhinitis levocetirizine dihydrochloride tablets are indicated for the relief of symptoms associated with perennial allergic rhinitis in adults and children 6 months of age and older. the use of levocetirizine dihydrochloride tablet is contraindicated in: 4.1 patients with known hypersensitivity patients with known hypersensitivity to levocetirizine or any of the ingredients of levocetirizine dihydrochloride tablets, or to cetirizine. observed reactions range from urticaria to anaphylaxis [see adverse reactions (6.2)]. 4.2 patients with end-stage renal disease patients with end-stage renal disease (clcr < 10 ml/min) and patients undergoing hemodialysis 4.3 pediatric patients with impaired renal function children 6 months to 11 years of age with impaired renal function 8.1 pregnancy pregnancy category b there are no adequate and well-controlled studies in pregnant women. because animal reproduction studies are not always predictiv

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

a-s medication solutions - levocetirizine dihydrochloride (unii: sod6a38aga) (levocetirizine - unii:6u5ea9rt2o) - levocetirizine dihydrochloride 5 mg - levocetirizine dihydrochloride tablets are indicated for the relief of symptoms associated with perennial allergic rhinitis in children 6 months to 2 years of age. levocetirizine dihydrochloride tablets are indicated for the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 months of age and older. the use of levocetirizine dihydrochloride is contraindicated in: patients with known hypersensitivity to levocetirizine or any of the ingredients of levocetirizine dihydrochloride, or to cetirizine. observed reactions range from urticaria to anaphylaxis [see adverse reactions (6.2) ]. patients with end-stage renal disease (clcr < 10 ml/min) and patients undergoing hemodialysis. children 6 months to 11 years of age with impaired renal function. pregnancy category b there are no adequate and well-controlled studies in pregnant women. because animal reproduction studies are not always predictive of human response, levocetirizine dihydrochloride should be used

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

a-s medication solutions - cetirizine hydrochloride (unii: 64o047ktoa) (cetirizine - unii:yo7261me24), pseudoephedrine hydrochloride (unii: 6v9v2ryj8n) (pseudoephedrine - unii:7cuc9ddi9f) - antihistamine nasal decongestant

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

bryant ranch prepack - cetirizine hydrochloride (unii: 64o047ktoa) (cetirizine - unii:yo7261me24) - cetirizine hydrochloride 10 mg - antihistamine temporarily relieves these symptoms due to hay fever or other upper respiratory allergies: - runny nose - sneezing - itchy, watery eyes - itching of the nose or throat

Beļģija - angļu - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

teva pharma belgium - levocetirizine (di)hydrochloride - film-coated tablet - 5 mg - levocetirizine (di)hydrochloride 5 mg - levocetirizine

Malta - angļu - Malta Medicines Authority

galpharm healthcare limited - cetirizine hydrochloride - film-coated tablet - cetirizine hydrochloride 10 milligram(s) - antihistamines for systemic use

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

synthon pharmaceuticals, inc. - levocetirizine dihydrochloride (unii: sod6a38aga) (levocetirizine - unii:6u5ea9rt2o) - levocetirizine dihydrochloride 5 mg - levocetirizine dihydrochloride tablets are indicated for the relief of symptoms associated with seasonal allergic rhinitis in adults and children 6 years of age and older. pediatric use information in pediatric patients (age 2 to 5 years) with seasonal allergic rhinitis is approved for ucb inc.'s levocetirizine dihydrochloride drug product. however, due to ucb inc.'s marketing exclusivity rights; this drug product is not labeled for such use in those pediatric patients. levocetirizine dihydrochloride tablets are indicated for the relief of symptoms associated with perennial allergic rhinitis in adults and children 6 years of age and older. pediatric use information in pediatric patients (age 6 months to 5 years) with perennial allergic rhinitis is approved for ucb inc.'s levocetirizine dihydrochloride drug product. however, due to ucb inc.'s marketing exclusivity rights; this drug product is not labeled for such use in those pediatric patients. levocetirizine dihydrochloride tablets are indicated for the trea

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

lannett company, inc. - levocetirizine dihydrochloride (unii: sod6a38aga) (levocetirizine - unii:6u5ea9rt2o) - levocetirizine dihydrochloride 0.5 mg in 1 ml - levocetirizine dihydrochloride oral solution is indicated for the relief of symptoms associated with perennial allergic rhinitis in children 6 months to 2 years of age. levocetirizine dihydrochloride oral solution is indicated for the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 months of age and older. the use of levocetirizine dihydrochloride is contraindicated in: patients with known hypersensitivity to levocetirizine or any of the ingredients of levocetirizine dihydrochloride, or to cetirizine. observed reactions range from urticaria to anaphylaxis [see adverse reactions (6.2)] . patients with end-stage renal disease (clcr < 10 ml/min) and patients undergoing hemodialysis children 6 months to 11 years of age with impaired renal function risk summary available data from published literature and postmarketing experience with levocetirizine use in pregnant women are insufficient to identify any drug-associated risks of miscarriage, birth defects

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

padagis israel pharmaceuticals ltd - levocetirizine dihydrochloride (unii: sod6a38aga) (levocetirizine - unii:6u5ea9rt2o) - levocetirizine dihydrochloride 0.5 mg in 1 ml - levocetirizine dihydrochloride is indicated for the relief of symptoms associated with perennial allergic rhinitis in children 6 months to 2 years of age. levocetirizine dihydrochloride is indicated for the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 months of age and older. the use of levocetirizine dihydrochloride is contraindicated in: patients with known hypersensitivity to levocetirizine or any of the ingredients of levocetirizine dihydrochloride, or to cetirizine. observed reactions range from urticaria to anaphylaxis [see adverse reactions (6.2)] . patients with end-stage renal disease (clcr < 10 ml/min) and patients undergoing hemodialysis. children 6 months to 11 years of age with impaired renal function. risk summary available data from published literature and post-marketing experience with levocetirizine use in pregnant women are insufficient to identify any drug-associated risks of miscarriage, birth defects, or adverse maternal or